XML 55 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborative Arrangements - Schedule of Collaborative Arrangement Transactions (Details) - Collaborative Arrangement - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Bayer AG          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Receivables from counterparty $ 27   $ 27   $ 33
Payables to counterparty 375   375   352
Bayer AG | Revenue          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Net product sales recorded by Merck 47 $ 36 90 $ 67  
Merck’s profit share from sales in Bayer's marketing territories 28 31 53 84  
Total sales 75 67 143 151  
Bayer AG | Materials and production          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses 132 24 159 47  
Bayer AG | Marketing and administrative          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses 10 5 17 11  
Bayer AG | Research and development          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses 28 $ 25 56 $ 51  
Eisai          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Receivables from counterparty 35   35    
Payables to counterparty 677   677    
Eisai | Revenue          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total sales 35        
Eisai | Materials and production          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses 1        
Eisai | Marketing and administrative          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses 2        
Eisai | Research and development          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses 36        
AstraZeneca          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Receivables from counterparty 40   40   12
Payables to counterparty 990   990   $ 643
AstraZeneca | Revenue          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total sales 44   76    
AstraZeneca | Materials and production          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses 24   36    
AstraZeneca | Marketing and administrative          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses 9   16    
AstraZeneca | Research and development          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expenses $ 42   $ 71